NCT03556579

The Effects of Contact Lenses With Experimental Dye on Visual Function

Name: Clinical Trial NCT03556579
Creator: Johnson & Johnson Vision Care, Inc.
Keywords: Ametropia, senofilcon A with new UV blocker, device, clinical trial, United States of America

Johnson & Johnson Vision Care, Inc.·ClinicalTrials.gov·device·Device trialCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Ametropia
Drug/Device/Intervention: senofilcon A with new UV blocker
Study type: Interventional
Intervention type: device

Sponsor & location

Primary sponsor: Johnson & Johnson Vision Care, Inc.
Location: Statesboro, United States of America

Timeline & enrollment

Phase: N/A
Start date: May 15, 2018
End date: Sep 20, 2018
Enrollment: 62 participants

Primary outcome

Two-Point Light Spread Function,Halos,Starburts

Summary

This is a single-site, two-visit, contralateral, non-dispensing, randomized, controlled and subject-masked study to measure potential benefits of the new UV blocker.

ICD-10 classifications

Amblyopia ex anopsiaAmoebiasisAmoebiasis, unspecifiedMyoclonusOesophagitis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT03556579
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT03556579 through Pure Global AI's free database. This phase not specified trial is sponsored by Johnson & Johnson Vision Care, Inc. and is currently Completed. The study focuses on Ametropia. Target enrollment is 62 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.